0.67%
-0.45%
-0.15%
41.36%
52.34%
83.15%
92.73%
AI Spotlight on EXEL
Company Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States.The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors.
The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan.In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma.Exelixis, Inc.
has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F.Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited.The company was formerly known as Exelixis Pharmaceuticals, Inc.
and changed its name to Exelixis, Inc.in February 2000.Exelixis, Inc.
was incorporated in 1994 and is headquartered in Alameda, California.
Market Data
| Last Price | 33.15 |
| Change Percentage | 0.67% |
| Open | 32.92 |
| Previous Close | 32.93 |
| Market Cap ( Millions) | 9467 |
| Volume | 1877637 |
| Year High | 37.59 |
| Year Low | 20.02 |
| M A 50 | 34.75 |
| M A 200 | 27.37 |
Financial Ratios
| FCF Yield | 4.47% |
| Dividend Yield | 0.00% |
| ROE | 21.26% |
| Debt / Equity | 8.55% |
| Net Debt / EBIDTA | -10.05% |
| Price To Book | 4.16 |
| Price Earnings Ratio | 20.27 |
| Price To FCF | 22.36 |
| Price To sales | 4.55 |
| EV / EBITDA | 14.78 |
News
- Jan -27 - Exelixis Stock Falls as Oppenheimer Downgrades Rating to Perform
- Jan -25 - Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-001 Trial Evaluating Zanzalintinib Alone or in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer at ASCO GI 2025
- Jan -24 - Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors Presented at ASCO GI 2025
- Jan -22 - Revenues, Treatment Pipeline Driving Exelixis Higher
- Jan -21 - EXEL vs. TECH: Which Stock Is the Better Value Option?
- Jan -21 - 4 PEG-Based Value Stocks to Neutralize Trump 2.0-Led Market Volatility
- Jan -14 - Why Exelixis (EXEL) is Poised to Beat Earnings Estimates Again
- Jan -14 - 5 Biotech Stocks Worth Adding to Your Portfolio in 2025
- Jan -13 - Exelixis Provides Preliminary 2024 Results and Outlook for 2025
- Jan -12 - Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025
- Jan -10 - The Best Defensive Stocks To Hedge Against Market Uncertainty
- Jan -10 - FDA Updates EXEL on Previously Scheduled ODAC Meeting for Cabozantinib
- Jan -09 - Exelixis: Bullish On Cabo, Not So Convinced By It's Long-Term Replacement, Zanza
- Jan -09 - No FDA advisory meeting for Exelixis a positive, says Citi
- Jan -09 - Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors
- Jan -06 - Exelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025
- Jan -06 - Exelixis Stock Surges 50% in a Year: Is There Room for Further Growth?
- Dec -25 - EXEL vs. INCY: Which Stock Should Value Investors Buy Now?
- Dec -19 - Exelixis downgraded to Market Perform from Outperform at BMO Capital
- Dec -19 - 4 Biotech Stocks Most Wall Street Analysts Are Bullish About
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Medicines for Difficult-to-treat Cancers
Expected Growth : 9.0 %
What the company do ?
Exelixis, Inc. develops medicines for difficult-to-treat cancers, including cabozantinib, a therapy for renal cell carcinoma and hepatocellular carcinoma.
Why we expect these perspectives ?
Exelixis' medicines for difficult-to-treat cancers drive 9.0% growth, fueled by increasing adoption of Cabometyx in renal cell carcinoma, expansion into new indications, and strong demand for Cometriq in medullary thyroid cancer. Additionally, strategic partnerships and investments in R&D accelerate pipeline development, further boosting growth.
Exelixis, Inc. Products
| Product Range | What is it ? |
|---|---|
| Cabometyx | A tablet formulation of cabozantinib, a small molecule inhibitor of multiple receptor tyrosine kinases, including VEGFR, MET, and AXL, for the treatment of advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). |
| Cometriq | A capsule formulation of cabozantinib, a small molecule inhibitor of multiple receptor tyrosine kinases, including VEGFR, MET, and AXL, for the treatment of progressive, metastatic medullary thyroid cancer (MTC). |
| Cotellic | A MEK inhibitor, used in combination with vemurafenib, a BRAF inhibitor, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. |
Exelixis, Inc.'s Porter Forces
Threat Of Substitutes
Exelixis, Inc. has a moderate threat of substitutes due to the availability of alternative cancer treatments. However, the company's focus on developing novel therapies with improved efficacy and safety profiles helps to mitigate this threat.
Bargaining Power Of Customers
Exelixis, Inc. has a low bargaining power of customers due to the specialized nature of its products and the lack of alternative treatment options for certain types of cancer.
Bargaining Power Of Suppliers
Exelixis, Inc. has a moderate bargaining power of suppliers due to its reliance on a limited number of suppliers for raw materials and manufacturing services. However, the company's strong relationships with its suppliers help to mitigate this risk.
Threat Of New Entrants
Exelixis, Inc. faces a high threat of new entrants due to the attractiveness of the oncology market and the increasing number of biotech companies focused on cancer research and development.
Intensity Of Rivalry
Exelixis, Inc. operates in a highly competitive oncology market with several established players, leading to a high intensity of rivalry. The company must continue to innovate and differentiate its products to maintain its market position.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 8.70% |
| Debt Cost | 3.95% |
| Equity Weight | 91.30% |
| Equity Cost | 6.78% |
| WACC | 6.54% |
| Leverage | 9.53% |
Exelixis, Inc. : Quality Control
Exelixis, Inc. passed 6 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| CORT | Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a … |
| NVAX | Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a … |
| ACLX | Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which … |
| RPRX | Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, … |
| ALPN | Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Exelixis
A-Score
1-Year Total Return ->
🥈
Royalty Pharma
A-Score
1-Year Total Return ->
🥉
Corcept Therapeutics
A-Score
1-Year Total Return ->
4
Novavax
A-Score
1-Year Total Return ->
5
Alpine Immune Sciences
A-Score
1-Year Total Return ->
6
